Clinical Trial Update: A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency [Phase 4]

View source ↗

Summary

Post-marketing Phase 4 study assessing immunogenicity of Nutropin AQ (somatropin) in children with growth hormone deficiency; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• Nutropin AQ (somatropin)

Snippet

Sponsor: Genentech, Inc. | Conditions: Growth Hormone Deficiency | Phase 4 | Status: COMPLETED | Results posted: 2018-11-15